AB Science
AB Science is a Paris biotechnology company built around masitinib, an oral tyrosine kinase inhibitor aimed at mast cells and macrophages that it has tested in phase 3 trials across cancers and neurological diseases.
Overview
AB Science, listed on Euronext Paris, develops masitinib, an oral tyrosine kinase inhibitor that acts on KIT, LYN and other kinases in mast cells and macrophages. The company has run a long series of phase 3 trials with masitinib in cancers including pancreatic cancer, prostate cancer, mastocytosis and gastrointestinal stromal tumours, and in amyotrophic lateral sclerosis, multiple sclerosis and Alzheimer's disease, and has faced repeated regulatory setbacks; the drug is not approved for cancer in the United States or the European Union. It appears on OnCo as one of the most active industry sponsors of phase 3 cancer trials on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyOrion, Orion Pharma
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag ctgov-sponsor.
- CompanyCEBIOTEX
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyBavarian Nordic
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyFutureChem
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyHinova Pharmaceuticals
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanySpectraCure
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.